Clinical Trials Directory

Trials / Unknown

UnknownNCT03963037

Characterization of Two Novel Mutations in the Apob Gene

Characterization of Two Novel Truncating Mutations in the Apob Gene Leading to Hypobetalipoproteinemia: A Pilot Study

Status
Unknown
Phase
Study type
Observational
Enrollment
16 (estimated)
Sponsor
Medical University Innsbruck · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers

Summary

The pilot study has the target to evaluate the outcomes of two novel mutations in the gene of Apolipoprotein B (ApoB). ApoB is the main part of the low-density lipoprotein (LDL). LDL is the main transporter of cholesterol from the liver to the periphery. The two novel mutations lead to a heavily truncated Apolipoprotein B. Therefore the patients show severely decreased ApoB and LDL-Cholesterol levels. The acquired disease is known as "Familial Hypobetalipoproteinemia". Beside the protection from cardiovascular disease due to decreased LDL-Cholesterol, patients tend to show elevated serum aminotransferases, fatty liver and occasional cases of cirrhosis and carcinoma. To elucidate the differences in lipoprotein assembly the investigators aim to characterize the changes due to the mutations in the patients. Family members not carrying the mutations are the control group. The assessment includes lipoprotein fractionation, MRI scans of the liver and a thorough assessment of medical history of all patients to look for potential side effects of the mutation. The only intervention needed for the study is to draw blood samples of every participant. The necessary positive vote from the ethics committee of the Medical University of Innsbruck is given.

Conditions

Interventions

TypeNameDescription
OTHERBlood drawDraw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.

Timeline

Start date
2019-01-24
Primary completion
2021-01-01
Completion
2022-01-01
First posted
2019-05-24
Last updated
2020-02-20

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT03963037. Inclusion in this directory is not an endorsement.